Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

28.09 -0.21 (-0.74%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
99 100 Next >
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
These seven companies were the top 2020 stocks. After their glory years have faded, they are looking to turn their fortunes around. 
Via InvestorPlace
Pfizer Seeks Expanded Use Of Abrysvo As Vaccine Shows Potential In 18+ Patients
Discover pivotal Phase 3 trial results for Pfizer's Abrysvo vaccine in adults 18-59 at risk of severe RSV disease. Achieved immunogenicity and safety milestones pave the way for potential regulatory... 
Via Benzinga
Decoding Pfizer's Options Activity: What's the Big Picture?
Via Benzinga
How's AT&T Handling Things?
We've also got a look at 3M's spinoff, gold prices, and the beef industry. 
Via The Motley Fool
2 Ultra-High-Yield Dividend Stocks to Buy and Hold Forever
A rate cut would likely be a boon for these two ultra-high yield dividend stocks. 
Via The Motley Fool
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
From Pfizer Inc.
Via Business Wire
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
These companies are close to launching new products that could supercharge revenue. 
Via The Motley Fool
3 Dirt-Cheap Stocks That Could Make You Filthy Rich
Cheap stocks offer a silver lining as the Fed takes a cautious stance, presenting opportunities for savvy investors. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Billionaire Ken Griffin Loaded Up on This High-Yield Dividend Stock. Should You?
The current status of this stock might seem bleak. But like a chess grandmaster, Griffin is looking several moves ahead. 
Via The Motley Fool
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
These stocks, a bargain today, are players to hold on to for the long term. 
Via The Motley Fool
Why Is Ocugen (OCGN) Stock Up 7% Today?
Ocugen is returning to its eye treatment roots after a brief life as a Covid-19 vaccine meme stock in 2021 delivered OCGN stock no results. 
Via InvestorPlace
Exposures COVID-19
Amazon, Alphabet And A Pharmaceutical Giant: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Jim Lebenthal of Cerity Partners said Amazon.com, Inc. (NASDAQ: AMZN) is on the 
Via Benzinga
The 3 Most Undervalued Healthcare Stocks to Buy in April 2024
Value investors looking for a deal should checkout these healthcare companies, each of which has a stock that looks undervalued. 
Via InvestorPlace
This S&P 500 Dividend Stock Could Be the Best Bad-News Buy on the Market
There could be a light at the end of the tunnel for this beaten-down stock. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Forget Nvidia: 3 Prominent Billionaire Investors Are Selling It and Buying These 6 Value Stocks Instead
Three highly successful billionaire money managers are paring down their respective stakes in artificial intelligence (AI) titan Nvidia and purchasing shares of six beaten-down value stocks. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
My Top-5 Ultrahigh-Yield Dividend Stocks to Buy in April
Let April showers rain down dividends on you with these great stocks. 
Via The Motley Fool
3 No-Brainer Dividend Stocks to Buy in April
Income investors will find a lot to like about these stocks. 
Via The Motley Fool
Got $1,000? 2 Phenomenal Growth Stocks to Buy in 2024 and Hold at Least a Decade
These stocks have unique buying propositions for long-term investors. 
Via The Motley Fool
The 7 Most Undervalued Russell 2000 Stocks to Buy in April 2024
With risk-on sentiment in place, investors may be looking for the most undervalued Russell 2000 stocks to buy in April. 
Via InvestorPlace
3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
The healthcare industry is one of the most potent yet also one of the most competitive. This has short sellers out for blood. 
Via InvestorPlace
Redditors Discuss What The Top 3 Value Stock Picks Are Right Now
Uncovering value amidst market fluctuations is a quest pursued by many investors. Reddit's r/ValueInvesting community shares insights on top 3 value picks: TSMC, Pfizer, and Berkshire Hathaway. 
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in April 2024
The most undervalued biotech stocks to buy in April are intriguing value options with mature biotech plays that boast impressive pipelines. 
Via InvestorPlace
Pfizer's Paxlovid Demonstrates Safety But Raises Questions on Efficacy in Low-Risk Covid-19 Patients-NEJM Study
New England Journal of Medicine publishes Pfizer's Paxlovid trial data, revealing insights into COVID-19 treatment efficacy, hospitalization rates, and adverse events. Learn more about the study's... 
Via Benzinga
Exposures COVID-19
3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
These stocks could outperform the broad market while they deliver heaps of dividend income. 
Via The Motley Fool
The Comeback Kids: 7 Stocks Ready to Rise from the Ashes
Discover seven resilient comeback stocks thriving across diverse sectors, from pharma to tech, poised for growth amid economic flux. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster
Sanofi reaches a settlement in principle for about 4,000 Zantac lawsuits in the US, excluding Delaware, regarding alleged cancer risks linked to NDMA. Financial terms remain undisclosed. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race
AstraZeneca's CEO Pascal Soriot celebrates hitting a $45 billion sales target set a decade ago despite initial skepticism. Investor confidence remains a challenge amid stagnant shares and concerns over... 
Via Benzinga
Merger Mania: 3 Potential Takeover Targets to Watch for Lucrative Buyouts
With interest rates poised to fall, acquisitions will become more numerous. Here are three potential takeover targets. 
Via InvestorPlace
Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era
Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) did not only earn billions of dollars from their COVID-19 leading products but also rose to fame for saving the world from an unforeseen pandemic. 
Via Benzinga
Exposures COVID-19
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.